Retrospective Cohort Study
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Oct 15, 2018; 9(10): 165-171
Published online Oct 15, 2018. doi: 10.4239/wjd.v9.i10.165
Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study
Hidetaka Hamasaki, Yasuteru Hamasaki
Hidetaka Hamasaki, Endocrinology and Metabolism, Internal Medicine, Hamasaki Clinic, Kagoshima 890-0046, Japan
Yasuteru Hamasaki, Diabetes, Hamasaki Clinic, Kagoshima 890-0046, Japan
Author contributions: Hamasaki H and Hamasaki Y equally contributed to study conception, data acquisition, data analysis, interpretation, and writing of article.
Institutional review board statement: This study protocol was reviewed and approved by the Japan Medical Association Ethical Review Board.
Informed consent statement: Study participants are assured that collected data will be used only for this study and will not be disclosed without the consent of the participants.
Conflict-of-interest statement: The authors declare no conflict of interest.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Hidetaka Hamasaki, MD, PhD, Doctor, Endocrinology and Metabolism, Internal Medicine, Hamasaki Clinic, Nishida 2-21-4, Kagoshima 890-0046, Japan. hhamasaki78@gmail.com
Telephone: +81-99-2503535 Fax: +81-99-2501470
Received: June 25, 2018
Peer-review started: June 25, 2018
First decision: July 9, 2018
Revised: July 12, 2018
Accepted: August 26, 2018
Article in press: August 26, 2018
Published online: October 15, 2018
Processing time: 110 Days and 7.6 Hours
ARTICLE HIGHLIGHTS
Research background

Dipeptidyl peptidase-4 (DPP-4) inhibitors are extensively used in patients with type 2 diabetes mellitus (T2DM). DPP-4 inhibitors can improve dyslipidemia and hypertension in addition to glycemic control.

Research motivation

Anagliptin is a unique DPP-4 inhibitor that possibly reduces the low-density lipoprotein cholesterol levels; however, it is not commonly available outside Japan. Few studies have directly compared the efficacy of anagliptin with other gliptins in the management of T2DM.

Research objectives

To assess the comparative effectiveness of anagliptin and linagliptin on the glycemic control, blood pressure, lipid profile, and liver and renal function in Japanese patients with T2DM.

Research methods

A 2-year retrospective cohort study in a diabetes-specialty clinic.

Research results

Both anagliptin and linagliptin effectively improved glycemic control for 2 years. Interestingly, diastolic blood pressure was reduced following the administration of anagliptin, and serum high-density lipoprotein cholesterol levels were increased following the administration of linagliptin. However, no significant changes in serum low-density lipoprotein cholesterol levels were observed in both the anagliptin group and the linagliptin group.

Research conclusions

This study adds to the current literature supporting that the efficacy of DPP-4 inhibitors on metabolic parameters may differ between anagliptin and linagliptin. Both DPP-4 inhibitors may have a unique effect beyond the class effect of DPP-4 inhibitors. However, whether a substantial clinical difference exists in the effect of DPP-4 inhibitors on metabolic parameters is still inconclusive because this study is a retrospective cohort study.

Research perspectives

We suggest the need for well-designed, large-scale studies to elucidate the effect of DPP-4 inhibitors on metabolic parameters beyond the glucose-lowering effect. Furthermore, comparative efficacy of DPP-4 inhibitors for arterial stiffness should also be investigated in the future.